Literature DB >> 16619000

Mismatch repair protein expression and microsatellite instability: a comparison of clear cell sarcoma of soft parts and metastatic melanoma.

Joaquin J Garcia1, Miranda J Kramer, Richard J O'Donnell, Andrew E Horvai.   

Abstract

Clear cell sarcoma of soft parts is a rare soft tissue malignancy that shows phenotypic overlap with cutaneous melanoma but can be distinguished by the presence of a t(12;22) translocation. Microsatellite instability (MSI), a variation in the lengths of short repeat DNA segments in the genome, has been implicated in melanoma tumorigenesis, but is rare or absent in clear cell sarcoma. Defects in the mismatch repair (MMR) enzyme complex correlate with MSI in some tumor types, allowing the use of immunohistochemistry for the MMR proteins hMLH1 and hMSH2 to predict the presence of MSI. To determine if the association between MMR defects and MSI extends to clear cell sarcoma, we compared a group of nine clear cell sarcomas to 11 metastatic melanomas on the basis of MSI and the expression of MMR proteins. MSI was studied using fluorescence-based multiplexed PCR of five loci. Immunohistochemistry was evaluated on formalin-fixed paraffin-embedded tissue for hMLH1, hMHS2 and hMSH6. MSI was present in only 1/9 (11%) clear cell sarcoma case and in 8/11 (73%) melanoma cases. Immunostaining for hMLH1 and hMSH2 was preserved in all the clear cell sarcomas but loss of immunostaining for one or both proteins was seen in 6/11 melanomas (55%). hMSH6 was detected in 7/9 (78%) clear cell sarcomas and 10/11 (91%) of melanomas. Clear cell sarcoma and metastatic melanoma differed significantly with respect to the presence of MSI (P=0.010) and staining for hMLH1 and/or hMSH2 (P=0.014) but not hMSH6 (P=0.57). Mismatch repair, and consequently genomic instability may contribute to tumorigenesis in melanoma but not clear cell sarcoma. Immunostaining for hMLH1 and hMSH2 and MSI analysis may be helpful in the differential diagnosis of large soft tissue or visceral malignancies with melanocytic differentiation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16619000     DOI: 10.1038/modpathol.3800611

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  9 in total

Review 1.  Emerging biomarkers for cancer immunotherapy in melanoma.

Authors:  Margaret L Axelrod; Douglas B Johnson; Justin M Balko
Journal:  Semin Cancer Biol       Date:  2017-09-14       Impact factor: 15.707

2.  Cutaneous clear cell sarcoma: a clinicopathologic, immunohistochemical, and molecular analysis of 12 cases emphasizing its distinction from dermal melanoma.

Authors:  Markus Hantschke; Thomas Mentzel; Arno Rütten; Gabriele Palmedo; Eduardo Calonje; Alexander J Lazar; Heinz Kutzner
Journal:  Am J Surg Pathol       Date:  2010-02       Impact factor: 6.394

3.  Distinct genetic profiles of extracranial and intracranial acral melanoma metastases.

Authors:  Gaurav Sharma; Christine G Lian; William M Lin; Ali Amin-Mansour; Judit Jané-Valbuena; Levi Garraway; Wendi Bao; Charles H Yoon; Nageatte Ibrahim
Journal:  J Cutan Pathol       Date:  2016-06-29       Impact factor: 1.587

4.  Immunohistochemical mismatch repair proteins expression as a tool to predict the melanoma immunotherapy response.

Authors:  Giovanni Ponti; Giovanni Pellacani; Aldo Tomasi; Roberta Depenni; Monia Maccaferri; Antonio Maiorana; Giulia Orsi; Francesca Giusti; Stefano Cascinu; Marco Manfredini
Journal:  Mol Clin Oncol       Date:  2019-11-07

5.  Histopathological and Molecular Profiling of Clear Cell Sarcoma and Correlation with Response to Crizotinib: An Exploratory Study Related to EORTC 90101 "CREATE" Trial.

Authors:  Che-Jui Lee; Elodie Modave; Bram Boeckx; Silvia Stacchiotti; Piotr Rutkowski; Jean-Yves Blay; Maria Debiec-Rychter; Raf Sciot; Diether Lambrechts; Agnieszka Wozniak; Patrick Schöffski
Journal:  Cancers (Basel)       Date:  2021-12-01       Impact factor: 6.639

6.  Soft Tissue Leiomyosarcoma With Microsatellite Instability, High Tumor Mutational Burden, and Programmed Death Ligand-1 Expression Showing Pathologic Complete Response to Pembrolizumab: A Case Report.

Authors:  Timothy Kwang Yong Tay; Joe Poh Sheng Yeong; Eileen Xueqin Chen; Xin Xiu Sam; Johnathan Xiande Lim; Jason Yongsheng Chan
Journal:  JCO Precis Oncol       Date:  2022-07

7.  Clear cell sarcoma: a case mimicking primary cutaneous malignant melanoma.

Authors:  M Rodríguez-Martín; M Sáez-Rodríguez; B Esquivel; R Sánchez Gonzáalez; A Noda Cabrera; A Martín Herrera
Journal:  Indian J Dermatol       Date:  2009       Impact factor: 1.494

8.  Microsatellite instability in sarcoma: fact or fiction?

Authors:  Michael J Monument; Stephen L Lessnick; Joshua D Schiffman; Rl Tx Randall
Journal:  ISRN Oncol       Date:  2012-07-18

9.  Mismatch repair deficiency is rare in bone and soft tissue tumors.

Authors:  Suk Wai Lam; Marie Kostine; Noel F C C de Miranda; Patrick Schöffski; Che-Jui Lee; Hans Morreau; Judith V M G Bovée
Journal:  Histopathology       Date:  2021-06-08       Impact factor: 5.087

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.